SLC6A4 and TPH2 methylation as potential biomarkers to inform antidepressant treatment choices
Silvia Elisabetta Portis Bruzzone, Brice Ozenne, Patrick MacDonald Fisher, Gabriela Ortega, Gitte Moos Knudsen, Klaus Peter Lesch, Vibe Gedsoe Frokjaer · FENS Forum 2024
Selective serotonin reuptake inhibitors (SSRI) are the most commonly prescribed class of antidepressants. However, SSRIs are frequently ineffective and precision medicine approaches are strongly needed to optimize treatment efficacy. DNA methylation levels of serotonin transporter (SLC6A4m) and tryptophan hydroxylase 2 (TPH2m) genes have been suggested as predictive biomarkers of antidepressant efficacy. In this study, we aimed to evaluate SLC6A4m/TPH2m biomarker potential and compare with previous findings in an independent cohort of N=77 patients with major depressive disorder who were treat
ePoster · Neuroscience